US biotech Gilead Sciences (Nasdaq: GILD) has announced its first-quarter 2024 financial results.
Sales at the Californian company hit $6.65 billion, a 5% rise on the same period of 2023 and ahead of the average analyst projection of $6.34 billion.
Gilead reported a first-quarter loss after taking a $3.9 billion charge for its recent acquisition of liver drug developer CymaBay Therapeutics, though the adjusted quarterly loss of $1.32 a share was still better than the $1.48 per share loss forecast by analysts.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze